Skip to main content
BPH ENERGY LTD logo

BPH ENERGY LTD — Investor Relations & Filings

Ticker · BPH ISIN · AU000000BPH4 ASX Financial and insurance activities
Open in API
Filings indexed 1,483 across all filing types
Latest filing 2009-03-17 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BPH

About BPH ENERGY LTD

https://www.bphenergy.com.au/

BPH Energy Ltd is a diversified investment company focused on the commercialization of biomedical technologies and the exploration of energy resources. The company maintains a significant portfolio in the biotechnology sector, notably through its investment in Cortical Dynamics Ltd, which develops the Brain Anaesthesia Response Monitor (BARM) for objective measurement of anesthetic effect. In the energy sector, BPH Energy holds a substantial interest in Advent Energy Ltd, an unlisted oil and gas exploration company with assets including the PEP 11 permit in the offshore Sydney Basin. Additionally, the company has expanded its focus into sustainable energy through investments in Clean Hydrogen Technologies, which utilizes proprietary processes to produce turquoise hydrogen and solid carbon. BPH Energy aims to identify and develop high-growth opportunities within the healthcare and resource sectors to create long-term value.

Recent filings

Filing Released Lang Actions
Appendix 3B 8 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class, number, terms, issue price, purpose, and dates related to the securities. It also includes sections on quotation of securities and warranties to the ASX (Australian Securities Exchange). The document is a formal announcement of a new issue of shares and application for quotation of additional securities, consistent with regulatory requirements for such announcements. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice. Therefore, the document fits the category of a Share Issue/Capital Change announcement.
2009-03-17 English
Change of Director`s Interest Notices 9 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including direct and indirect holdings, dates of changes, number of securities held before and after changes, and nature of changes such as issuance of shares for director fees. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, earnings, or management discussion, but focuses solely on directors' share dealings. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains detailed transaction data, confirming it is not a mere announcement or certification. Therefore, the correct classification is DIRS.
2009-03-17 English
Novel Cancer Therapeutic Discovery 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 March 2009 from BioPharmica Limited. It discusses a novel cancer therapeutic discovery, describing the scientific background, technology, and opportunity for co-development of a drug candidate. The content is promotional and informational about a new drug discovery and development opportunity, rather than financial results, regulatory filings, or management changes. There are no financial statements, earnings data, or regulatory compliance information. The document is not a report but an announcement of a scientific and business opportunity. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories, which is Regulatory Filings (RNS).
2009-03-11 English
Half Yearly Report and Accounts 18 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half Year Financial Report For the half year ended 31 December 2008' and contains detailed financial statements including consolidated income statement, balance sheet, statement of changes in equity, cash flow statement, notes to the financial statements, directors' report, auditor's independence declaration, and directors' declaration. The report is prepared in accordance with Australian Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001, indicating it is a formal interim financial report. The content includes actual financial data and analysis for a half-year period, not just an announcement or certification. Therefore, this document is an Interim / Quarterly Report (IR). H1 2009
2009-02-23 English
Notice of General Meeting/Proxy Form 10 pages ?Kb
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'NOTICE OF GENERAL MEETING' for Biopharmica Limited, dated March 18, 2009. It includes details about the meeting time, place, agenda, and resolutions to be voted on, specifically about the placement of shares to directors. It contains an explanatory statement providing information to shareholders to help them decide on the resolutions. It also includes proxy voting instructions and voting exclusions. The content is focused on informing shareholders about the meeting and soliciting their votes on specific resolutions, rather than reporting financial results or management commentary. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The document is not an actual report like an Annual Report or Interim Report, nor is it a voting results announcement or a regulatory filing. Therefore, the correct classification is PSI with high confidence.
2009-02-17 English
HLS5 presented at the Lorne Cancer Conference 2009 2 pages ?Kb
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 16 February 2009 from BioPharmica Limited. It reports on a scientific presentation (a poster) given at the 21st Lorne Cancer Conference 2009. The content focuses on research findings related to a gene (HLS5) and its role in cancer, including details of the research collaboration and abstract from the poster. There is no financial data, no mention of financial results, no regulatory filings, no management or board changes, no voting results, no capital or financing updates, and no legal proceedings. The document is essentially a corporate announcement about a scientific presentation and research update. It is not a report, transcript, or financial filing. Given the nature and length (3222 characters), it is not a report publication announcement or regulatory filing. The best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2009-02-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.